BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22099210)

  • 1. Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy.
    Maylin S; Laouénan C; Martinot-Peignoux M; Panhard X; Lapalus M; Nicolas-Chanoine MH; Bedossa P; Asselah T; Marcellin P
    J Clin Virol; 2012 Jan; 53(1):43-7. PubMed ID: 22099210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.
    Moucari R; Asselah T; Cazals-Hatem D; Voitot H; Boyer N; Ripault MP; Sobesky R; Martinot-Peignoux M; Maylin S; Nicolas-Chanoine MH; Paradis V; Vidaud M; Valla D; Bedossa P; Marcellin P
    Gastroenterology; 2008 Feb; 134(2):416-23. PubMed ID: 18164296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
    Barreiro P; Martín-Carbonero L; Núñez M; Rivas P; Morente A; Simarro N; Labarga P; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Apr; 42(7):1032-9. PubMed ID: 16511772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
    Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
    J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury.
    Adinolfi LE; Andreana A; Utili R; Zampino R; Ragone E; Ruggiero G
    Am J Gastroenterol; 1998 Nov; 93(11):2162-6. PubMed ID: 9820390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection.
    Hsu CS; Liu CH; Liu CJ; Hsu SJ; Chen CL; Hwang JJ; Lai MY; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2010 May; 25(5):970-7. PubMed ID: 20546452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
    Patton HM; Patel K; Behling C; Bylund D; Blatt LM; Vallée M; Heaton S; Conrad A; Pockros PJ; McHutchison JG
    J Hepatol; 2004 Mar; 40(3):484-90. PubMed ID: 15123364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.
    Rafi H; Kabbaj N; Salihoun M; Amrani L; Acharki M; Guedira M; Nya M; Amrani N
    Arab J Gastroenterol; 2011 Sep; 12(3):136-8. PubMed ID: 22055591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of intrahepatic HCV RNA level in chronic HCV infection].
    Jang JY; Kim YS; Kim SG; Kim YS; Cho YD; Lee JS; Jin SY; Lee MS; Kim JH; Shim CS; Kim BS
    Korean J Hepatol; 2006 Dec; 12(4):515-23. PubMed ID: 17237629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin changes in HCV-Genotype 4: relation to liver histology and response to treatment.
    Derbala M; Rizk N; Al-Kaabi S; Amer A; Shebl F; Al Marri A; Aigha I; Alyaesi D; Mohamed H; Aman H; Basem N
    J Viral Hepat; 2009 Oct; 16(10):689-96. PubMed ID: 19486470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
    Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
    Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients.
    Shahid M; Idrees M; Nasir B; Raja AJ; Raza SM; Amin I; Rasul A; Tayyab GU
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):788-94. PubMed ID: 24781355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.